Skip Navigation
Alvotech

Better Access. Better Lives.

We are led by science, driven by passion, and committed to biosimilars. We are continually evaluating additional pipeline opportunities to bring a strategic and robust selection of treatment options to patients around the world.

  • AVT02

    Biosimilar candidate
    High-concentration, low-volume adalimumab
    Reference biologic
    HUMIRA®
    Therapeutic area
    Immunology

    Approved by

    • U.S.
    • Europe (EEA, UK, Switzerland, Balkans)
    • Canada
    • Australia
    • Saudi Arabia
    • Israel
    • Egypt
    • South Africa
    • Morocco
    • Peru
    • Bolivia
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT04

    Biosimilar candidate
    ustekinumab
    Reference biologic
    STELARA®
    Therapeutic area
    Immunology

    Approved by

    • U.S.
    • Japan
    • Canada
    • EU/EEA
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT03

    Biosimilar candidate
    denosumab
    Reference biologic
    PROLIA®/XGEVA®
    Therapeutic area
    Bone Disease

    Approved by

    • Japan
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT05

    Biosimilar candidate
    golimumab
    Reference biologic
    SIMPONI®/SIMPONI ARIA®
    Therapeutic area
    Immunology

    Approved by

    • Japan
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT06

    Biosimilar candidate
    aflibercept
    Reference biologic
    EYLEA®
    Therapeutic area
    Ophthalmology

    Approved by

    • EEA
    • Japan
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT23*

    Biosimilar candidate
    omalizumab
    Reference biologic
    XOLAIR®
    Therapeutic area
    Respiratory
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT16

    Biosimilar candidate
    vedolizumab
    Reference biologic
    ENTYVIO®
    Therapeutic area
    Immunology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT33

    Biosimilar candidate
    pembrolizumab
    Reference biologic
    KEYTRUDA®
    Therapeutic area
    Oncology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT10

    Biosimilar candidate
    certolizumab pegol
    Reference biologic
    CIMZIA®
    Therapeutic area
    Immunology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT28

    Biosimilar candidate
    ixekizumab
    Reference biologic
    TALTZ®
    Therapeutic area
    Immunology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT48

    Biosimilar candidate
    canakinumab
    Reference biologic
    ILARIS®
    Therapeutic area
    Immunology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT41

    Biosimilar candidate
    guselkumab
    Reference biologic
    TREMFYA®
    Therapeutic area
    Immunology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT65

    Biosimilar candidate
    ofatumumab
    Reference biologic
    KESIMPTA®
    Therapeutic area
    Immunology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT19

    Biosimilar candidate
    dupilumab
    Reference biologic
    DUPIXENT®
    Therapeutic area
    Immunology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch

HUMIRA is a registered trademark of AbbVie Inc.
STELARA, SIMPONI and SIMPONI ARIA are registered trademarks of Johnson & Johnson Inc.
XOLAIR, ILARIS and KESIMPTA is a registered trademark of Novartis AG.
PROLIA and XGEVA are registered trademarks of Amgen Inc.
EYLEA and EYLEA HD are registered trademarks of Regeneron Pharmaceuticals Inc. and Bayer AG.
ENTYVIO is a registered trademark of Millenium Pharmaceuticals Inc.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp.

CIMZIA is a registered trademark of UCB Pharma S.A.

DUPIXENT is a registered trademark of Sanofi Biotechnology.

TALTZ is a registered trademark of Eli Lilly and Company.